Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)
Study Details
Study Description
Brief Summary
The purpose of this study is to assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injection in subjects with severe or critical COVID-19 disease.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
This is a Phase 2b/3, two-arm, randomized, double blind, placebo controlled, adaptive design multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients with severe or critical symptoms of respiratory illness caused by coronavirus 2019 infection. Patients will be randomized to receive weekly doses of 700 mg leronlimab (PRO 140), or placebo. Leronlimab (PRO 140) and placebo will be administered via subcutaneous injection.
A single arm, non-randomized, open-label phase is added to the protocol after completion of enrollment in the Randomized Phase of the study.
The study will have three phases: Screening Period, Treatment Period, and Follow-Up Period.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Placebo Comparator: Placebo
|
Drug: Placebos
Placebos
|
| Experimental: 700mg Leronlimab
|
Drug: Leronlimab (700mg)
Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
|
Outcome Measures
Primary Outcome Measures
- All-cause mortality at Day 28 [Day 28]
Day 0 refers to the data of randomization/first treatment.
Secondary Outcome Measures
- All-cause mortality at Day 14 [Day 14]
Day 0 refers to the data of randomization/first treatment.
- Change in clinical status of subject at Day 14 (on a 7 point ordinal scale) [Day 14]
A 7-category ordinal scale of patient health status ranges from: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities.
- Change in clinical status of subject at Day 28 (on a 7 point ordinal scale) [Day 28]
A 7-category ordinal scale of patient health status ranges from: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities.
- Change from baseline in Sequential Organ Failure Assessment (SOFA) score at Day 14. [Day 14]
The SOFA score assessment will be based on PaO2/FiO2, platelets, Glasgow coma scale (GCS), bilirubin, Mean arterial pressure OR administration of vasoactive agents required, and Serum creatinine
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male or female adult ≥ 18 years of age at time of screening.
-
Subjects hospitalized with severe or critical illness caused by coronavirus 2019 infection as defined below:
A. Severe Illness:
- Diagnosed with COVID-19 by standard RT-PCR assay or equivalent testing within 5 days of screening
AND
Symptoms of severe systemic illness/infection with COVID-19:
- At least 1 of the following: fever, cough, sore throat, malaise, headache, muscle pain, shortness of breath at rest or with exertion, confusion, or symptoms of severe lower respiratory symptoms including dyspnea at rest or respiratory distress
AND
Clinical signs indicative of severe systemic illness/infection with COVID-19, with at least 1 of the following:
- RR ≥ 30, HR ≥ 125, SaO2 <93% on room air or requires > 2L oxygen by NC in order maintain SaO2 ≥93%, PaO2/FiO2 <300
AND
- None of the following: Respiratory failure (defined by endotracheal intubation and mechanical ventilation, oxygen delivered by high-flow nasal cannula, noninvasive positive pressure ventilation, or clinical diagnosis of respiratory failure in setting of resource limitations), Septic shock (defined by SBP < 90 mm Hg, or Diastolic BP < 60 mm Hg), Multiple organ dysfunction/failure
B. Critical Illness:
- Diagnosed with COVID-19 by standard RT-PCR assay or equivalent testing within 5 days of screening
AND
Evidence of critical illness, defined by at least 1 of the following:
- Respiratory failure defined based on resource utilization requiring at least 1 of the following: Endotracheal intubation and mechanical ventilation, oxygen delivered by high-flow nasal cannula, noninvasive positive pressure ventilation, ECMO, or clinical diagnosis of respiratory failure (in setting of resource limitation)
OR
- Shock (defined by SBP < 90 mm Hg, or Diastolic BP < 60 mm Hg or requiring vasopressors)
OR
-Multiple organ dysfunction/failure
- Subject, if intubated, positive endexpiratory pressure (PEEP) <15 cmH2O with PaO2/FiO2
150 mmHg.
-
Electrocardiogram (ECG) with no clinically significant findings as assessed by the Investigator
-
Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures.
-
Understands and agrees to comply with planned study procedures.
-
Women of childbearing potential and their partner must agree to use at least one highly effective method of contraception (e.g., hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], intrauterine devices, bilateral tubal occlusion, or sexual abstinence) for the duration of the study.
Exclusion Criteria:
-
Subjects with do-not-resuscitate (DNR) and/or do-not-intubate (DNI) orders or expected to be made DNR/DNI in setting of resource limitations or family wishes.
-
Not a candidate for dialysis or continuation of care (or full medical support) in setting of resource limitations.
-
Subject on continuous vasopressors (at the dose of norepinephrine >20μg/min and/or vasopressin >0.04 units/kg/min) for >48 hours at time of screening.
-
Subjects who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to leronlimab (PRO 140) are not eligible.
-
Inability to provide informed consent or to comply with test requirements
-
Consideration by the investigator, for safety reasons, that the subject is an unsuitable candidate to receive study treatment
-
Pregnancy or breast feeding
-
Subject participating in another study with for an investigational treatment for COVID-19.
Note: Subject who were prescribed (1) hydroxychloroquine or chloroquine with or without azithromycin, (2) Remdesivir, (3) convalescent plasma therapy, or (4) immunomodulatory treatments (including but not limited to sarilumab, clazakizumab, tocilizumab, and anakinra) for the off-label treatment of COVID-19 prior to study enrollment may be included and may continue to receive these agents as part of standard-of-care.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Advanced Cardiovascular, LLC | Alexander City | Alabama | United States | 35010 |
| 2 | St. Jude Medical Center | Fullerton | California | United States | 92835 |
| 3 | UCLA | Los Angeles | California | United States | 90095 |
| 4 | James A. Haley Veterans' Hospital | Tampa | Florida | United States | 33612 |
| 5 | Center for Advanced Research & Education (CARE) | Gainesville | Georgia | United States | 30501 |
| 6 | Beth Israel Deaconess Medical Center | Boston | Massachusetts | United States | 02215 |
| 7 | St. Barnabas | Livingston | New Jersey | United States | 07052 |
| 8 | Atlantic Health System Hospital | Morristown | New Jersey | United States | 07962-1905 |
| 9 | Holy Name Medical Center | Teaneck | New Jersey | United States | 07666 |
| 10 | Montefiore Medical Center | Bronx | New York | United States | 10467 |
| 11 | New York Community Hospital of Brooklyn | Brooklyn | New York | United States | 11229 |
| 12 | Novant Health | Winston-Salem | North Carolina | United States | 27103 |
| 13 | Ohio Health | Columbus | Ohio | United States | 43215 |
| 14 | Good Samaritan Hospital Corvallis | Corvallis | Oregon | United States | 97330 |
| 15 | Oregon Health and Sciences University | Portland | Oregon | United States | 97239 |
| 16 | Baylor Scott & White Research Institute | Dallas | Texas | United States | 75204 |
| 17 | Baylor College of Medicine | Houston | Texas | United States | 77030 |
| 18 | University of Texas | Houston | Texas | United States | 77030 |
Sponsors and Collaborators
- CytoDyn, Inc.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CD12_COVID-19